Pa. Jury Returns $3.65 Million Verdict in Actos Bladder Cancer Case

PHILADELPHIA — A jury has returned a verdict of more than $2.3 million in non-economic and compensatory damages and $1.3 million in punitive damages in favor of a Pennsylvania man who alleged that his bladder cancer was caused by Takeda Pharmaceuticals Inc.’s diabetes drug Actos.

After deliberating for eight hours, the Philadelphia Court of Common Pleas jury on Feb. 12 awarded John Kristufek $2 million in non-economic damages and $318,000 in compensatory damages.

On Feb. 13, the jury awarded Kristufek $1.3 million in punitive damages after finding that Takeda had acted with reckless indifference in failing to adequately warn …